Vytrus Biotech S.A. (VYT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has a cash flow conversion efficiency ratio of 0.047x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€225.55K ≈ $263.69K USD) by net assets (€4.75 Million ≈ $5.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Vytrus Biotech S.A. for the company's overall valuation and market capitalisation.
Vytrus Biotech S.A. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Vytrus Biotech S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vytrus Biotech S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vytrus Biotech S.A. ranked by their cash flow conversion efficiency. Explore VYT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AYER Holdings Bhd
KLSE:2305
|
0.075x |
|
Nynomic AG
F:M7U
|
-0.045x |
|
YESASIA HOLDINGS LTD
F:4CM
|
N/A |
|
Origin Property PCL
BK:ORI
|
0.023x |
|
Amulaire Thermal Technology
TW:2241
|
0.007x |
|
Securitag Assembly Group Co Ltd
TWO:6417
|
0.023x |
|
NH SPAC 2
KQ:206640
|
0.043x |
|
MEDIFAST INC
NYSE:MED
|
0.009x |
Annual Cash Flow Conversion Efficiency for Vytrus Biotech S.A. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Vytrus Biotech S.A. from 2020 to 2025. View Vytrus Biotech S.A. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.31 Million ≈ $12.05 Million |
€3.90 Million ≈ $4.56 Million |
0.378x | +49.65% |
| 2024-12-31 | €7.29 Million ≈ $8.53 Million |
€1.84 Million ≈ $2.16 Million |
0.253x | +47.95% |
| 2023-12-31 | €5.29 Million ≈ $6.19 Million |
€904.39K ≈ $1.06 Million |
0.171x | +260.14% |
| 2022-12-31 | €4.75 Million ≈ $5.56 Million |
€225.55K ≈ $263.69K |
0.047x | -54.97% |
| 2021-12-31 | €4.25 Million ≈ $4.97 Million |
€447.92K ≈ $523.67K |
0.105x | +387.17% |
| 2020-12-31 | €3.61 Million ≈ $4.22 Million |
€-132.47K ≈ $-154.87K |
-0.037x | -- |
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more